Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12330919 | 0.92 | LMNA (0.52) | CD274LMNADRD2 | |
| SCHEMBL39934 | 0.90 | CD274 (0.60) | CD274TDP1POLBCACNA1HSMN1; SMN2 | |
| SCHEMBL4753694 | 0.88 | CD274 (0.54) | CD274TDP1POLBCACNA1HSMN1; SMN2 | |
| SCHEMBL9093109 | 0.82 | CD274 (0.53) | CD274TDP1POLBCACNA1HSMN1; SMN2 | |
| SCHEMBL39968 | 0.82 | LMNA (0.58) | CD274LMNADRD2 | |
| SCHEMBL21217985 | 0.80 | CD274 (0.46) | CD274TDP1SMN1; SMN2LMNADRD2 | |
| SCHEMBL2850188 | 0.80 | CD274 (0.51) | CD274TDP1LMNADRD2 | |
| SCHEMBL24172673 | 0.79 | DRD2 (0.56) | CD274TDP1CACNA1HDRD2KMT2A | |
| SCHEMBL31301250 | 0.79 | DRD2 (0.56) | CD274TDP1CACNA1HDRD2KMT2A | |
| SCHEMBL4024516 | 0.79 | DRD2 (0.56) | TDP1CACNA1HDRD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018039641-A1 | METHODS AND COMPOUNDS FOR TREATING ALCOHOL USE DISORDERS AND ASSOCIATED DISEASES | PHARMATROPHIX, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
| US-9464066-B2 | Deuterated compounds useful for treating neurodegenerative diseases | PHARMATROPHIX, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | Ricerca Biosciences, LLC | 2016-08-11 | — | — | US | disclosed |
| WO-2010102212-A2 | NEUROTROPHIN MIMETICS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2010-09-10 | — | — | WO | disclosed |
| WO-2008155141-A2 | NOVEL FACULTATIVE CATONIC STEROLS | NOVOSOM AG (DE) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229823-A1 | DEUTERATED COMPOUNDS USEFUL FOR TREATING NEURODEGENERATIVE DISEASES | NLN, NGF, BDNF | CD274 2371/4885TDP1 666/4885POLB 2957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.